AbbVie's New Crohn's Disease Drug Candidate

AbbVie's (NYSE: ABBV  ) drug Humira is currently the best-selling medication on the planet, and it is approved to treat a wide range of diseases, including Crohn's Disease and ulcerative colitis. Recently, the company announced a partnership with a small biotech company called Galapagos to develop a JAK1 inhibitor for Crohn's Disease. In the following video, health-care analyst Max Macaluso discusses the details behind this deal and how this drug can potentially help the company maintain its lead in the autoimmune disease market in the coming years.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2442544, ~/Articles/ArticleHandler.aspx, 7/30/2014 1:40:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement